Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207895 · ClinicalTrials.gov registry record · Phase 1
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
A Phase 1 study of Rectal Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT01207895: Completed Phase 1 study of Rectal Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
NCT01207895 is a Phase 1 study of Rectal Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 5 participants, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01207895, a Phase 1 study of Rectal Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if positron emission tomography (PET) imaging with an imaging agent called 18F-fluorodeoxythymidine(\[18F\]-FLT) will allow investigators to measure how well tumor(s) respond to treatment without taking a tissue sample (biopsy). Additionally, the investigators want to determine if it is possible to predict how well tumor(s) might respond to treatment with \[18F\]-FLT PET imaging.
Primary Outcome
Ability of this imaging technique to determine growth of cancer cells and as a quantitative biomarker of response to relevant, molecularly targeted, therapies
Conditions Studied
Interventions
- DEVICE PET imaging with [18F]-FLT
- DRUG [18F]-fluorodeoxythymidine
Study Locations (1)
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
What the finished NCT01207895 record still lists
NCT01207895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which PET imaging with [18F]-FLT is the first listed.
NCT01207895 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT01207895 about?
NCT01207895 is a clinical study titled "Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer". The purpose of this study is to determine if positron emission tomography (PET) imaging with an imaging agent called 18F-fluorodeoxythymidine(\[18F\]-FLT) will allow investigators to measure how well tumor(s) respond to treatment without taking a tissue sample (biopsy). Additionally, the investigato...
What is the current status of trial NCT01207895?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-03. Estimated completion is 2013-07.
What conditions does trial NCT01207895 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT01207895?
The interventions under investigation include: PET imaging with [18F]-FLT (DEVICE), [18F]-fluorodeoxythymidine (DRUG).
Who is sponsoring clinical trial NCT01207895?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01207895 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01207895's enrollment target sits among peer trials
5 71st of 70 the lowest of 70 other Rectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
F-Tryptophan PET/CT in Human Cancers
RECRUITING · Phase 1
-
Ultra-fractionated Radiotherapy for Rectal Cancer
RECRUITING · Phase 1
-
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
RECRUITING · Phase 1
-
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia